Solid phase synthetic technique for thymosin alpha1

A technology of solid-phase synthesis and thymosin, which is applied in the field of thymosin α1, can solve the problems of violent reaction, high production cost, and low yield, and achieve the effects of mild reaction conditions, safety of production personnel, and reduction of production cost

Active Publication Date: 2008-01-16
苏州天马医药集团天吉生物制药有限公司
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] With comprehensive reference to the preparation methods of thymosin α1 and related synthesis reports at home and abroad, it is found that these technologies have some deficiencies, which are mainly manifested in: ①Biosynthesis technology single molecule Escherichia coli is difficult to express, and it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solid phase synthetic technique for thymosin alpha1
  • Solid phase synthetic technique for thymosin alpha1
  • Solid phase synthetic technique for thymosin alpha1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Embodiment 1: Synthesis of Fmoc-Asp (Rink Amide AM Resin)-OtBu

[0051] Add 2g of Fmoc-Rink Amide AM Resin, with a substitution degree of 1.1mmol / g, into a solid-phase reactor, add 20ml of DCM to swell the resin for 30min, and remove Fmoc protection twice with 20% DBLK5+10min to obtain NH 2 -Rink Amide AM Resin, washed 4 times in DMF and 2 times in DCM.

[0052] Dissolve 0.91g of Fmoc-Asp-OtBu, 0.4ml of DIC, and 0.327g of HOBt in 4ml of DMF, activate in ice water at low temperature for 10min, add to the above solid-phase reactor, and react at room temperature for 2h. After washing twice with DMF, 6.2 ml of acetic anhydride and 5.3 ml of pyridine were added to react for 4 hours to block unreacted free amino groups on the resin. After washing twice with DMF, it was shrunk with methanol for 10+10 min to obtain Fmoc-Asp(Rink Amide AM Resin)-OtBu, and the detected substitution degree was 0.453mmol / g.

Embodiment 2

[0053] Example 2: AA 1-27 -Synthesis of Asp(resin)-OtBu

[0054] Weigh 2.2g of Fmoc-Asp(Rink Amide AM Resin)-OtBu with a degree of substitution of 0.453mmol / g, add to the reactor and swell with DCM for 0.5 hours, then remove Fmoc with 20% DBLK (5+5)min, wash Then connect the 27th amino acid Fmoc-Glu(OtBu)-OH, dissolve 1.702g Fmoc-Glu(OtBu)-OH, 1.517gHBTU, 0.149gHOBt in 5mlDMF, add 1mlDIPEA after 10 ice baths; after low temperature activation for 10min, add the above solid In the phase reactor, react at room temperature for 1-2 hours, and the end point of the reaction is determined by the ninhydrin method. Repeat the above steps, and so on to complete the connection of amino acids from 26 to 1 to obtain AA 1-27 -Asp(resin)-OtBu. Raw material dosage: amino acid 1.0mmol, HBTU 1.517g, HOBt 0.149g, DIPE Alml.

Embodiment 3

[0055] Example 3: Ac-AA 1-27 -Synthesis of Asp(resin)-OtBu

[0056] Add 2.8ml of acetic anhydride and 2.4ml of pyridine in the reactor, and react at room temperature for 4 hours. The ninhydrin method resin is colorless and transparent, and the reaction is complete. The acetylation reagent is removed, washed twice with DMF, and shrunk with methanol (10+10 )min, Ac-AA was obtained after drying under reduced pressure for 6 hours 1-27 -Asp(resin)-OtBu 4.9 g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a solid-phase synthesis process of a thymosin alpha 1, belonging to the polypeptide solid-phase synthesis technical field. The invention comprises the following steps: a. a Fmoc-Rink Amide AM resin or a Fmoc-Rink Amide MBHA resin is used as carrier, an H2N-Rink Amide AM resin or an H2N-Rink Amide MBHA resin is obtained after deprotection of the Fmoc; b. side chain carboxyl group of Fmoc-Asp-X is connected with resin amino by the method of solid-phase synthesis to obtain the Fmoc-Asp (resin)-X; c. the left amino acid in the sequence is synthesized in solid-phase with the Fmoc strategy; d. after the amino protection group Fmoc of N terminal amino acid is removed, the N terminal amino acid is acetylated by acetic anhydride and pyridine; e. then the acetylated N terminal amino acid is cut by a cracking agent (tri fluoroacetic acid/ benzoylate sulfide/1, 2- dithioglycol/ Anisole) to obtain the thymosin alpha 1; f. crude product of the thymosin alpha 1 is prepared and separated by HPLC to obtain the pure thymosin alpha 1. The invention can increase significantly the yield of the thymosin alpha 1 and decrease the production cost, which is helpful for scale production and has better industrialization prospect.

Description

technical field [0001] The invention relates to a polypeptide whose C-terminus is Asn, in particular to thymosin α1, especially the solid-phase synthesis process of thymosin α1. Background technique [0002] Thymosin α1 is a single-component polypeptide compound present in the thymus of mammals. It is a molecule related to the development and differentiation of immune cells. It can differentiate and proliferate T lymphocytes, improve cellular immune function, and destroy the target cells it infects. , It can also activate NK cell activity and promote the production of immune-related cytokines. The activity of thymosin α1 is 10 to 1,000 times higher than that of thymopentin. It is a compound drug for the treatment of chronic hepatitis B, hepatitis C, and immunodeficiency syndrome. It also plays a greater role in the treatment of non-small cell lung cancer and malignant melanoma. Thymosin α1 was developed and marketed by Italian company Sciclone in 1997. It has been approved ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/66C07K14/47C07K1/04
CPCY02P20/55
Inventor 初虹
Owner 苏州天马医药集团天吉生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap